CAV 200 Pill - beige capsule/oblong, 14mm
Generic Name: capivasertib
Pill with imprint CAV 200 is Beige, Capsule/Oblong and has been identified as Truqap 200 mg. It is supplied by AstraZeneca.
Truqap is used in the treatment of Breast Cancer and belongs to the drug class multikinase inhibitors. Truqap 200 mg is not a controlled substance under the Controlled Substances Act (CSA).
Images for CAV 200
Truqap
- Generic Name
- capivasertib
- Imprint
- CAV 200
- Strength
- 200 mg
- Color
- Beige
- Size
- 14.00 mm
- Shape
- Capsule/Oblong
- Availability
- Prescription only
- Drug Class
- Multikinase inhibitors
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- AstraZeneca
- National Drug Code (NDC)
- 00310-9501
See also:
Trodelvy
Trodelvy (sacituzumab govitecan) is a targeted therapy used to treat breast cancer (triple-negative ...
Enhertu
Enhertu is a treatment for breast cancer, stomach cancer, and non-small cell lung cancer with HER2 ...
Verzenio
Verzenio is used to treat early and advanced-stage hormone receptor-positive, HER2-negative breast ...
Kisqali
Kisqali (ribociclib) is used to treat a certain type of advanced metastatic breast cancer. Includes ...
Keytruda
Keytruda is used to treat multiple types of cancer such as melanoma, non-small cell lung cancer ...
Arimidex
Arimidex is used to treat breast cancer in postmenopausal women. Learn about side effects ...
Femara
Femara lowers estrogen levels and is used to treat breast cancer in postmenopausal women. Learn ...
Herceptin
Herceptin is used to treat patients with metastatic breast cancer. Learn about side effects ...
Ibrance
Ibrance is used to treat HR-positive, HER2-negative breast cancer in postmenopausal women or men ...
More about Truqap (capivasertib)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: multikinase inhibitors
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.